Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
“We published a reflective article on why the uptake of gene therapy in hemophilia is less than expected. It’s not due to lack of interest in gene therapy in general by patients and health care providers, as some have alleged, but related to more complex problems including the differing benefit/risk balance of individual gene therapies and need for more creative reimbursement frameworks. Medicines with strong efficacy and safety have been, and will continue to be embraced by the community. We look forward to advancing technological improvements in gene therapies, including gene editing, especially for hemophilia A, and to more enthusiasm of biopharma to reach 85% of the world having substandard or no treatment.”
To learn more, follow the link.
Read the full article here.
Article: Why is the uptake of gene therapy in hemophilia less than expected?
Authors:
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Oct 8, 2026, 12:45Pedro Perez: World Thrombosis Day 2026 – Raising Awareness of Women’s VTE Risk
-
Oct 8, 2026, 12:20Berrin Gunaydin: Functional Biomarkers of Iron Deficiency in Pregnancy
-
Oct 8, 2026, 11:45Wolfgang Miesbach: Milvexian After Acute Coronary Syndrome – What LIBREXIA ACS Found
-
Oct 8, 2026, 11:36John Erbey: Kidney Disfunction as a Cause of Anemia
-
Oct 8, 2026, 11:31Navneet Mishra: Sitosterolemia as an Under-Recognised Cause of Cytopenias
-
Oct 8, 2026, 11:06Houman Khosravani: Stroke and Thrombosis – Bridging Neurology and Hemostasis
-
Oct 8, 2026, 04:28Jeff Molter: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 04:23Barbara Adams Krolak: Women and Blood Clots Are We Missing the Warning Signs
-
Oct 8, 2026, 04:10Rutendo Muzambi: Hospital Admission Patterns and Care Disparities in Sickle Cell Disease